In the same compassionate use case series, 12 patients (75%) developed CRS, 1 (6%) developed ICANS, and 6 (37.5%) received tocilizumab, the anti‐IL6 monoclonal antibody commonly used to treat CRS. This evidence concerns the gene IL6 and congenital rubella syndrome.